JAMA Oncology —The Year in Review, 2023

2023 Has been a busy year for JAMA Oncology and its editors. We have had the pleasure of receiving a substantial number of submissions and reviewing an exciting array of scientific studies, opinions, and reviews. The use of artificial intelligence to bolster the oncology workforce was one of our most popular topics, but the verdict is still out on whether a chatbot can ace the medical, surgical, or radiation oncology board examinations. We continued to learn more this year about the role of physical activity in preventing cancer recurrence and even in preventing multiple different types of cancer. Although several studies have evaluated different intensities of activity, we still do not have an exact number to write on a physical activity prescription for each patient. We just know that we should probably give a physical activity prescription to each patient. We have reported results from several large phase 3 randomized clinical trials affecting standard of care, as well as exciting and promising results from smaller phase 1 and 2 studies with outstanding correlative science. And JAMA Oncology continues to publish important studies reporting the global health impact of cancer. We hope that you enjoyed reading these articles as much as we enjoyed choosing them for publication.

Leggi
Maggio 2024

Access to Reproductive Services and Catholic Hospitals

Hospitals with Catholic affiliations have a growing presence in the health care ecosystem. The tenets of Catholic health care services position them as important providers of services and advocates for “people whose social condition puts them at the margins of our society” and thus are well positioned to provide care to those most vulnerable individuals in our society. However, the same tenets prohibit contraceptive services unless they treat serious conditions with no alternative treatment and refusal to provide services that are not aligned with the religious tenets.

Leggi
Maggio 2024

JAMA Oncology

JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.

Leggi
Maggio 2024